Abstract: An apparatus for forming a C1 to C5 oxygenate from carbon dioxide and a C1 to C4 hydrocarbon is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the C1 to C4 hydrocarbon and an outlet for the oxygenates. In one example the passageway includes therein a catalyst. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide in reacted with the C1 to C4 hydrocarbon in the generated plasma, thereby forming the oxygenates from at least some of the carbon dioxide and the C1 to C4 hydrocarbon. The DBD device comprises a conducting liquid as a ground electrode. A method and a use are also described.

Abstract: A display panel and a display device are provided. The display panel includes a pixel driving circuit, a scan line, and a light-emitting control line connected to the pixel driving circuit. The pixel driving circuit includes a driving transistor, a first reset module, and a light-emitting element. An output terminal of the first reset module is connected to a gate of the driving transistor and an output terminal of the driving transistor is electrically connected to the light-emitting element. An input terminal of the first reset module is connected to the scan line or the light-emitting control line. A scan signal provided by the scan line or a light-emitting control signal provided by the light-emitting control line is multiplexed as a first reset signal provided by the reset module to the gate of the driving transistor.

Abstract: An apparatus for forming C1 to C5 alcohol, carboxylic acid, or mixture thereof from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the C1 to C5 alcohol, carboxylic acid, or mixture thereof and including therein a catalyst comprising nickel and/or cobalt and/or copper on a support. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the C1 to C5 alcohol, carboxylic acid, or mixture thereof from at least some of the carbon dioxide and the hydrogen. The DBD devices comprises a water electrode. A method and a catalyst are also described.

Abstract: Provided herein are novel thyroid hormone receptor (TR) agonists, e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.

Abstract: Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula A, B, C, D, E, or F, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting PI3K in a cell, and/or in treating various diseases such as cancer.

Abstract: Provided herein are novel thyroid hormone receptor (TR) agonists e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.

Abstract: Provided herein are novel compounds, for example, compounds having a structure according to Formula III-1 to III-12, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting DGKs in a cell, and/or in treating various diseases such as cancer or viral infections.

Abstract: Systems and methods are directed to selecting and delivering targeted content. In response to a request from a user, a central control component accesses content delivery data and content provider settings. Based on the content delivery data and the content provider settings, the central control component generates content delivery settings that include a plurality of frequency capping (Fcap) rules. The content delivery settings are transmitted to a serving system. A determination component of the serving system accesses user data associated with the user that indicates user preferences. Based on the content delivery settings and the user data, the determination component selects a piece of content to deliver to the user. A delivery component then delivers the piece of content to the user.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula I, Formula II-1 to II-7, Formula III-1 to III-9, IV, or V, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting DGKa and/or DGKz in a cell, and/or in treating various diseases such as cancer or viral infections.

Abstract: The present invention discloses a compound represented by formula 1a or formula 1b, an optical isomer, prodrug or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and their use in preparation of a CDK2 inhibitor

Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: A display panel and a display device are provided. The display panel includes a pixel driving circuit, a scan line, and a light-emitting control line connected to the pixel driving circuit. The pixel driving circuit includes a driving transistor, a first reset module, and a light-emitting element. An output terminal of the first reset module is connected to a gate of the driving transistor and an output terminal of the driving transistor is electrically connected to the light-emitting element. An input terminal of the first reset module is connected to the scan line or the light-emitting control line. A scan signal provided by the scan line or a light-emitting control signal provided by the light-emitting control line is multiplexed as a first reset signal provided by the reset module to the gate of the driving transistor.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Abstract: A display panel has a display region and a frame region outside the display region. The display region includes a plurality of pixel circuits. The display panel includes a base substrate, a buffer layer, a semiconductor layer, a power signal layer, and an auxiliary circuit layer. The buffer layer is on a side of the base substrate. The buffer layer includes an a-Si layer. The semiconductor layer is on a side of the buffer layer away from the base substrate. The power signal layer is on a side of the semiconductor layer away from the base substrate. The power signal layer includes a plurality of first power voltage lines in the display region, and one first power voltage line of the plurality of first power voltage lines are electrically connected to a corresponding pixel circuit.

Abstract: A display panel and a display device are provided. The display panel is divided into an active area and a non-active area. The non-active area is divided into a first area, a flexible area and a second area sequentially arranged towards the active area. The display panel includes a substrate, an array layer, a touch wiring and a first signal wiring. The touch wiring includes a first touch lead, a second touch lead and a third touch lead that are electrically connected. The first touch lead is at least partially arranged in the array layer on a side of a first via hole group away from the flexible area. This display panel is developed into an in-cell touch panel.

Abstract: Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.